A Rare Side Effect of Intravesical Bacillus Calmette-Guerin Therapy: Reactive Arthritis

Kizilgok B., İZOL V., ERKEN E., TANSUĞ M. Z.

UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, vol.17, no.1, pp.33-35, 2018 (ESCI) identifier

  • Publication Type: Article / Article
  • Volume: 17 Issue: 1
  • Publication Date: 2018
  • Doi Number: 10.4274/uob.915
  • Journal Name: UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY
  • Journal Indexes: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Page Numbers: pp.33-35
  • Çukurova University Affiliated: Yes

Abstract

Approximately 70-80% of bladder cancers are superficial tumors and not muscle invasive. Complete transurethral resection of the bladder tumour (TUR-BT) is the standard approach to these patients. Intravesical treatments such as adriamycin, doxorubicin, epirubicin, mitomycin-c and Bacillus Calmette-Guerin (BCG) may be performed after TUR-BT in order to prevent further recurrence or progression. BCG is generally used in high-risk patients and causes local or systemic side effects in less than 5% of patients. Osteoarticular side effects are very rare and usually manifest as joint pain and arthritis (%0.5-1). In this case report, we present the management of reactive arthritis in a patient treated with intravesical BCG for bladder cancer.